Steinfurt

This research evaluates two types of phakic toric implantable lenses, EYECRYLTM Phakic Toric and Visian4 Toric ICL, in patients with moderate to high myopia and astigmatism. These lenses are designed to correct vision by being implanted without removing the natural lens, allowing light to focus properly on the retina. The study aims to compare how effective each lens is and to assess their safety in improving uncorrected visual acuity for patients with these eye conditions. Participants will be randomly assigned to receive either the Eyecryl Phakic IOL or the Visian4 Toric Implantable Contact Lens. Both devices are surgically implanted in the eye's anterior or posterior chamber and are designed to correct both myopia and astigmatism. The study focuses on measuring the residual refractive error six months after implantation to compare the outcomes of these two treatments. During the study, participants will undergo regular evaluations to monitor their vision and eye health. Researchers will assess uncorrected visual acuity, refractive stability, and safety outcomes throughout the follow-up period. Patients must attend all scheduled visits and provide informed consent. The study includes a detailed assessment of visual outcomes and safety to determine the performance of each lens over time.

This research aims to gather detailed information about the use of assistive devices, medicines, and other healthcare supports like ventilation therapy and nutrition in patients with Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The goal is to understand real-world clinical practices and capture patient experiences through reported outcomes. The study collects extensive data including clinical details, medical history, functional assessment scales, prognosis indicators, biomarker and genetic information, and use of innovative and symptomatic drugs. The study does not involve experimental treatments but focuses on observing and recording the healthcare measures patients are currently receiving. Data includes the use of medications such as Tofersen, Nusinersen, and Risdiplam, as well as patient questionnaires assessing medication expectations and satisfaction. This registry study aims to capture comprehensive health data across different patient groups over an extended period. Participants provide information through questionnaires and clinical scales during follow-up, with neurological treatment details systematically recorded and evaluated by patients over a period of 10 years. The study collects ongoing data on treatment outcomes and patient experiences to better understand the management of these neurological conditions in everyday clinical settings.